Caspase-3 is an intracellular cysteine protease, activated as part of the apoptotic response to cell injury.
added substrate in staurosporine-treated SH-SY5Y cells. The AQZs reduce biochemical and cellular features of apoptosis that are thought to be a consequence of caspase-3 activation including DNA fragmentation, TUNEL staining, and the various morphological features that define the terminal stages of apoptotic cell death. Moreover, the AQZs also inhibit apoptosis induced by nerve growth factor withdrawal from differentiated PC12 cells. Thus, the AQZs represent a new and structurally novel class of inhibitors, some of which selectively inhibit caspase-3 and will thereby allow evaluation of the role of caspase-3 activity in various cellular models of apoptosis.
Apoptosis is an important cellular response to severe stress, resulting in the death of the cell. In some clinical conditions, dysregulation of apoptosis is thought to be an important contributor to the pathogenesis of disease. The molecular mechanisms that drive the apoptotic response have been clarified in recent years (Green and Reed, 1998; Strasser et al., 2000; Zornig et al., 2001) . These studies have led to the identification of distinct biochemical pathways, pharmacological perturbation of which could block the apoptotic response and possibly reverse the functional decline of affected cells. Indeed, some of these biochemical pathways contain molecular targets that may be amenable to therapeutic intervention. One such target is caspase-3, a cysteine protease activated in response to numerous cellular insults (Nicholson, 2000) .
Caspase-3 belongs to a family of cysteine proteases that consists of at least 14 members. These caspases can be subdivided based on structural homology, substrate preference, or biological function (Nicholson, 1999) . For example, several caspases have been shown to be important contributors to the inflammatory response by processing cytokines (caspase-1, -4, -5, and -13) whereas others are activated either as an early step in the initiation of apoptosis (caspase-6, -8, -9, and -10) or in the execution of the apoptotic response (caspase-2, -3, and -7). Caspase-3 has received particular attention from a therapeutic perspective because it is expressed in almost all tissues and at relatively high levels (versus other caspases) and has high catalytic activity compared with the other executioner caspases (Margolin et al., 1997; Garcia-Calvo et al., 1999; Stennicke et al., 2000) . Furthermore, genetic knockout studies have shown that caspase-3 plays a critical role in apoptosis during neuronal development (Kuida et al., 1996; Woo et al., 1998) , whereas other studies support a role in neurodegenerative diseases (Yakovlev et al., 1997; Gervais et al., 1999; Xu et al., 1999; Beer et al., 2000; Rigamonti et al., 2000; Wellington et al., 2000) .
Although structure-based design of inhibitors for caspase-3 have successfully produced potent, peptide and peptidomimetic compounds (Margolin et al., 1997; Garcia-Calvo et al., 1998; Karanewsky et al., 1998) , these inhibitors typically have pharmacokinetic and physicochemical properties that limit their utility to intravenous applications for acute disease treatments. The development of nonpeptidic inhibitors could overcome these limitations, but unfortunately such compounds have been difficult to identify and optimize. To date, the only examples published include a series of isatin sulfonamides, which, although potent inhibitors of caspase-3, have limited selectivity versus the other executioner caspases Nuttall et al., 2001) . In this report we describe the biochemical and cellular profile of a new series of potent and selective, nonpeptide caspase-3 inhibitors.
Materials and Methods
Materials. (Z-DEVD) 2 -R110 and Hoechst 33342 stain were purchased from Molecular Probes (Eugene, OR). PC12 cells and SH-SY5Y cells were purchased from American Type Culture Collection (Manassas, VA). Staurosporine, NGF, and anti-NGF antisera were obtained from Sigma-Aldrich (St. Louis, MO). Caspase-1,-2, -6, -7, -8, substrates Ac-YVAD-amc, Ac-LEHD-amc, and Ac-IETD-amc, and inhibitors Ac-YVAD-CHO, Ac-LEHD-CHO, Ac-IETD-CHO, and Ac-DEVD-CHO were obtained from Biomol Research Laboratories, Inc. (Plymouth Meeting, PA). Boc-Asp-fmk and Z-DEVD-fmk were purchased from Enzyme Systems Products (Livermore, CA). Caspase-6 was obtained from BD Biosciences (San Jose, CA). Recombinant human caspase-3 was expressed in Escherichia coli and purified from exclusion bodies using published procedures (Rotonda et.al.,1996) . Substrate Ac-DEVD-amc and the inhibitor Ac-DEVD-CHO were synthesized at AstraZeneca Pharmaceuticals LP (Wilmington, DE) . In situ cell death detection kit (TUNEL staining) was purchased from Roche Diagnostics (Indianapolis, IN).
Inhibitor Synthesis. The anilinoquinazolines (AQZs) were prepared as described (Jacobs et al., 2001) . The isatin sulfonamide named compound 33 was synthesized and purified using published procedures .
Enzyme Assays. The enzymatic activity of caspase-1, -2, -3, -6, -7, and -8 (40, 180, 100, 5, 1, and 10 ng, respectively) was determined from the initial rate of hydrolysis of their respective substrates (10 -50 M), by measuring at room temperature the accumulation of a fluorogenic product over time. The enzymes and substrates were diluted in assay buffer containing 150 mM NaCl, 50 mM HEPES, 5 mM EDTA, 1 mM dithiothreitol, 0.1% CHAPS (caspase-6 and -8), 10% glycerol, pH 7.0. The stock solutions for AQZs were prepared in dimethyl sulfoxide. Formation of the product, aminomethyl-coumarin, was detected by the increase in sample fluorescence ( ex ϭ 360 nm, em ϭ 460 nm) using a Victor plate reader (PerkinElmer Life Sciences, Boston, MA), taking sample readings every 1 to 2 min for up to 1 h. Intracellular DEVDase Assay. SH-SY5Y cells were maintained in Dulbecco's modified Eagle's medium plus 10% FCS. The cells were plated in 96-well plates at a density of 60,000 cells/well overnight and then the medium was replaced with PBS plus 10% FCS. The cells were incubated with (Z-DEVD) 2 -R110 (50 ⌴) with or without staurosporine (1 ⌴) and inhibitor for 4 h. The fluorescence intensity of each well was then measured using a microplate reader (Applied Biosystems, Foster City, CA) with excitation/emission wavelengths of 496 nm/520 nm. The cleaved product was also visualized at the single cell level by fluorescence microscopy using an Olympus IX70 inverted fluorescence microscope (20ϫ magnification) and WIB filters.
Cell Apoptosis Assays. The PC12 cell NGF withdrawal assay was performed as described previously (Bhat et al., 2000) . Briefly, PC12 cells were differentiated for 9 to 12 days in RPMI 1640 medium containing 1% FCS and 50 ng/ml NGF. The cells were extensively washed with NGF-free media, incubated with anti-NGF antibodies (1:400) plus inhibitors for 4 h, and then processed for DNA fragmentation.
DNA fragmentation was quantitated in both PC12 cells and SH-SY5Y cells using a capture ELISA as specified by the manufacturer (Roche Diagnostics, Indianapolis, IN; cell death detection kit, catalog number 1774425). This assay measures the appearance of mono-and oligonucleosomes in the cytoplasm that are the consequence of activating endogenous endonucleases during the apoptotic response. Briefly, cell samples are lysed and cytoplasmic fractions obtained. The cytoplasm samples are transferred to a streptavidin-coated microtiter plate and incubated with biotin-conjugated anti-histone antibodies and peroxidase-conjugated anti-DNA antibodies. The nucleosomes are captured with the anti-histone antibody and become immobilized on the streptavidin-coated plate. The anti-DNA antibody binds to the DNA component of the nucleosomes and, after washing the plate to remove any unbound antibodies, is quantified by measuring the amount of peroxidase activity in the well.
Cell viability was quantified using the Alamar Blue assay as described by the manufacturer (Trek Diagnostic Systems, Westlake OH). SH-SY5Y cells were incubated for 3 h with or without AQZs and in the presence or absence of 1 M staurosporine. Alamar Blue (resazurin) was then added to achieve 10% v/v and incubated an additional 3 h. The fluorescence intensity of each well was then measured using a microplate reader (Perseptive Biosystems) with excitation/emission wavelengths of 530 nm/580 nm. The results were expressed as percentage of viability compared with untreated cells.
Cell Staining. SY5Y cells were plated at 1.5E-5 cells per well in a 48-well plate. Cells were treated with staurosporine plus drugs as described for 4 h. Samples were fixed with 2% paraformaldehyde for 10 to 30 min at 4°C, washed once with PBS, then treated briefly with Hoechst 33342 stain (1:500). Cells were again washed with PBS. The cells were permeabilized using 0.1% Triton X-100 for the TUNEL staining, which was performed as recommended by the manufacturer. Fluorescence microscopy evaluation was visualized directly in the wells using a Nikon Diaphot microscope.
Data Analysis. Data are expressed as mean Ϯ S.E. from at least three independent experiments. Nonlinear regression analysis of concentration response curves was performed using GraphPad Prism (GraphPad Software Inc., San Diego, CA). Statistical analyses were performed using the Student's t test. p Ͻ 0.05 was considered statistically significant.
Results
Enzyme Assays. Random screening for inhibitors of recombinant human caspase-3 revealed a series of compounds termed anilinoquinazolines, or AQZs (Fig. 1 ). These compounds inhibited the rate of product formation in the fluorogenic enzyme assay in a concentration-dependent manner ( Fig. 2A) . A Dixon plot of the concentration-response data for AQZ-3 yielded a K i ϭ 589 nM. Additional AQZs were synthesized, primarily by varying the substituent at position R8, with several demonstrating similar or greater potency for caspase-3 (Table 1 ). In addition to modifications at R8, replacing the dichloroanilide moiety with a fluoroanilide resulted in a 6-fold increase in potency (compare compound AQZ-3 with compound AQZ-2). Compound AQZ-2 is the most potent inhibitor within the series, with a K i ϭ 88 nM.
The AQZs were evaluated for their inhibitory activity against several other members of the caspase family. As shown in Table 1 , the AQZs did not appreciably inhibit caspase-1, as all the compounds had K i values above 10 ⌴. In addition, the AQZs did not have appreciable activity against caspase-2 and -7, the two enzymes with greatest substrate similarity to caspase-3. Forty percent of the 26 AQZs tested showed some inhibition of caspase-6, with K i values ranging from 199 nM to 3.7 ⌴. None of the AQZs were more potent against caspase-6 versus caspase-3. Caspase-8 has similar substrate specificity as caspase-6, but this isoform was not inhibited by the AQZs. Thus, of the six caspases evaluated in the selectivity study, only caspase-3 was potently inhibited by the AQZs. AQZ-1 and AQZ-6 are examples of selective caspase-3 inhibitors and were further evaluated in cellular assays of caspase-3 activity.
Whole Cell Assays. A number of assays have been developed to monitor caspase-3 activity in cell lysates and the consequences of caspase-3 activation in intact cells, but methods to directly measure caspase-3 catalytic activity in intact cells are limited. Such an assay would help in the development and analysis of cell permeable caspase-3 inhibitors. For this reason, a new cellular assay was developed and used to determine whether intracellular caspase-3 activity was blocked by the AQZs and whether this correlated with inhibition of other features of apoptosis. (Z-DEVD) 2 -R110, a rhodamine-conjugated peptide substrate for caspase-3 that was reported to enter cells (Liu et al., 1999) , was used as substrate. This peptide is an internally quenched substrate; cleavage of the Z-DEVD blocking groups relieves the quench and allows fluorescence detection using appropriate excitation and emission wavelengths. SH-SY5Y cells were used for these studies, as their apoptotic response to a number of toxicants has been well studied (Posmantur et al., 1997; Bijur et al., 2000; Lopez and Ferrer, 2000) .
As shown in Fig. 3 , staurosporine-treated SH-SY5Y cells convert intracellular (Z-DEVD) 2 -R110 to the fluorescent product. In the absence of staurosporine, no fluorescent product was observed visually, either with or without AQZs. The appearance of the fluorescent product was quantified using a fluorescence microplate reader (Fig. 4) . There is a ϳ3-h time lag between staurosporine treatment and an increase in fluorescence. This lag time was also observed when measuring caspase-3 activity in lysates of these cells and presumably represents the time frame during which the staurosporine insult is translated into an apoptotic response via biochemical pathway(s) that culminate in the activation of caspase-3. After this lag time, there is a continual increase in fluorescence over several hours (the figure is restricted to a 2-h window to better visualize control versus stimulated signals). No increase in fluorescence was observed with untreated cells or in cells treated with staurosporine but not (Z-DEVD) 2 -R110.
It is possible that the fluorescence signal is not due to cleavage of (Z-DEVD) 2 -R110 by intracellular caspase-3 in cells undergoing apoptosis but rather reflects caspase-3 activity released into the culture media by dying cells. To determine whether the fluorescence signal truly reflects intracellular DEVDase activity, cell samples were taken at various times after staurosporine treatment and pelleted by centrifugation, the supernatant was removed and incubated with (Z-DEVD) 2 -R110. As shown in Fig. 4A , the isolated supernatant from these cells did not appreciably cleave the substrate, indicating that the DEVDase activity was not present in the cell culture media. Thus, the increased fluorescence represents cleavage of (Z-DEVD) 2 -R110 by intracellular caspase-3.
The fluorescence signal is dependent on the concentrations of (Z-DEVD) 2 -R110 and staurosporine used in the assay (Fig.  4, B and C) . The standard assay conditions include 50 ⌴ (Z-DEVD) 2 -R110, a concentration that is nearly saturating, and 1 ⌴ staurosporine. Other toxicants shown to activate caspase-3 in various cell types are also active in this assay including H 2 O 2 , camptothecin, actinomycin D, CCCP, and the proteosome inhibitor MG-132 (data not shown).
The potency and efficacy of caspase-3 inhibitors were assessed in this assay. As shown in Fig. 4D , both AQZ-3 and AQZ-1 completely blocked the staurosporine-induced intracellular DEVDase activity. This effect was dose-dependent, with IC 50 values of 5.7 and 14.9 ⌴ for AQZ-3 and AQZ-1, respectively.
Nonpeptide inhibitors of caspase-3 that have been reported in the literature include a group of isatin sulfonamides ) and dithiocarbamates such as disulfiram (Nobel et al., 1997) . The isatin sulfonamides are direct inhibitors of caspase-3 whereas the dithiocarbamates have been reported to block the processing/activation of the caspase-3 proenzyme. Selective examples of these compounds were also tested in this assay to determine whether structurally divergent caspase-3 inhibitors are effective in blocking the stau- jpet.aspetjournals.org rosporine response. Indeed, both the isatin sulfonamide and disulfiram were able to completely inhibit intracellular DEVDase activity and did so with IC 50 values of 9.5 Ϯ 3.2 ⌴ and 3.7 Ϯ 0.2 ⌴, respectfully.
Compounds that inhibit caspase-3 activity should block the downstream consequences of this enzyme's effects. One endstage biochemical event in apoptosis is the cleavage of chromosomal DNA into internucleosomal fragments. Caspase-3 promotes DNA degradation because it cleaves and inactivates ICAD, an inhibitor of the endonuclease responsible for degrading DNA (Green and Reed, 1998) . Since these DNA fragments are a hallmark feature of apoptosis, experiments were performed to determine whether the AQZs would inhibit staurosporine-induced DNA fragmentation. As shown in Fig. 5 , both AQZ-3 and AQZ-6 block DNA degradation in a dose-dependent fashion. The IC 50 values for AQZ-3 and AQZ-6 were 8.2 and 3.0 M, respectively, which is consistent with that required for inhibition of intracellular DEVDase activity.
The characteristic morphological changes that occur in apoptosis include general shape changes toward a rounded and shrunken phenotype with cytoplasmic blebbing and clumping or fragmentation of chromatin within the nucleus. These morphological features can be observed in staurosporine-treated SH-SY5Y cells using a combination of phasecontrast microscopy and Hoechst 33342 staining. As shown in Fig. 6 , staurosporine-treated cells lost their flat and extended appearance and became small rounded cells. Hoechst staining of control cells revealed a light background of diffusely stained nuclei. In cells exposed to staurosporine, the very small and intensely bright punctate deposits of Hoechst 33342 were prevalent, indicative of condensed nuclei. In contrast, SH-SY5Y cells treated with staurosporine plus AQZ-3 maintained a more normal and flattened phenotype, albeit with some retraction of neurite-like extensions. Cotreating with AQZ-3 reduced the appearance of punctate nuclear staining, suggesting a reduction in the number of cells containing condensed chromatin. Treating cells with AQZ-3 alone had no effect on their morphology or the appearance of punctate Hoechst staining (not shown). Cells treated with staurosporine plus 100 M Z-DEVD-fmk, an irreversible peptide inhibitor of caspases, had morphological features similar to that seen with AQZ-3 and lacked punctate Hoechst staining. These results indicate that caspase-3 inhibitors such as the AQZs can reduce the morphological features of apoptosis in SH-SY5Y cells, features that represent the terminal aspects of the apoptotic death pathway.
TUNEL staining is often used as a histochemical method to detect fragmented DNA. Although not a specific diagnostic for apoptosis, an increase in TUNEL staining is observed in cells undergoing apoptotic death. Compared with untreated SH-SY5Y cells, staurosporine treatment caused a large increase in the number of TUNEL positive cells (Fig. 6 , right column). Visualization by qualitative microscopy indicated that pretreating with AQZ-3 or Z-DEVD-fmk reduced the appearance of TUNEL positive cells. Cells treated with AQZ-3 alone appeared similar to untreated cells (not shown). Together, these data indicate that the AQZs can reduce the morphological features associated with apoptosis caused by staurosporine treatment.
Since the AQZs reduce DNA damage and morphological changes associated with the apoptotic death pathway induced by staurosporine treatment, experiments were performed to determine whether cell viability was enhanced by these caspase-3 inhibitors. The Alamar Blue assay was used to quantify cell viability. This assay is similar to the MTT assay in that it uses a chemical probe to measure the redox potential (metabolic activity) of cells. SH-SY5Y cells treated with 1 M staurosporine for 6 h had a reduction in cell viability to 64 Ϯ 7% (S.D.) of control cells whereas cells treated with staurosporine plus 10 M AQZ-1 had 92 Ϯ 2% viability. Cells treated with staurosporine plus 10 M AQZ-3 or AQZ-6 showed 89 Ϯ 1% and 93 Ϯ 2% viability, respectively. Cells treated with AQZs alone had viability values equivalent to untreated cells. These results indicate that the AQZs enhance cell viability in this cell culture apoptosis paradigm.
The efficacy of the AQZs at inhibition of apoptosis was determined in a well characterized cellular model of apoptosis. This experiment also ensures that their efficacy was not somehow restricted to one cell type. The PC12 cell growth 
factor-withdrawal model is an established assay in which differentiated PC12 cells are deprived of NGF, resulting in a rapid induction of caspase-3 activity and apoptosis (Haviv et al., 1997; Kim et al., 1999) . As shown in Fig. 7 , AQZs reduced the DNA fragmentation that occurs with NGF withdrawal. This inhibitory effect is also observed with the isatin sulfonamide and with boc-Asp-fmk, an irreversible and nonselective caspase inhibitor. The AQZs did not affect the level of DNA fragmentation seen in the presence of NGF. Thus, the AQZs are effective in preventing apoptosis induced by multiple cellular insults via a caspase-3-dependent mechanism.
Discussion
This study describes the biochemical and cellular properties of a new series of small molecule inhibitors of caspase-3. The AQZs are structurally distinct from the other known class of nonpeptide caspase-3 inhibitors, the isatin sulfonamides. However, both series share an electrophilic carbonyl that presumably represents the site of nucleophilic attack by the active site cysteine thiolate. This has been verified for the isatin sulfonamides using X-ray crystallography data . Although not formally proven, molecular modeling studies with the AQZs are consistent with this same mechanism of action.
The caspases chosen for selectivity assessment include members of each of the three major subgroups that are defined by substrate specificity at the P4 site (Nicholson, 1999) : caspase-1 (group I), caspase-2 and -7 (group II, which includes caspase-3), and caspase-6 and -8 (group III). The AQZs display selectivity within the caspase family, with caspase-6 being the only other isoform sensitive to inhibition, and this was observed with only a subset of the AQZs. No appreciable inhibition was observed with caspase-7, which is the isoform with highest structural homology to caspase-3. This selectivity is not seen with the isatin sulfonamides, which are at most Ͻ3-fold selective versus caspase-7. Therefore, the AQZs represent useful pharmacological tools to help delineate the relative importance of caspase-3 versus caspase-7 in the apoptotic response. These results also indicate that specificity for the AQZs does not fit within the subgroup families as defined by the P4 determinants, i.e., structural features other than S4 are important in defining the binding of AQZs to caspases.
The caspase-3 cellular assay described in this report has advantages over other cell-based assays described in the literature. The protocol is a simple mix-and-measure assay that can be used with both adherent and nonadherent cells. It can be used as an endpoint assay and is compatible with high density plates for use in random high throughput screening. Transfection of a reporter gene or other construct is not required, although it is compatible should one choose to evaluate the influence of other gene products on caspase-3 activity. Importantly, it is a direct measure of intracellular DEVDase activity rather than a downstream readout that could be modulated by other biochemical pathways. Although the AQZs are relatively potent inhibitors of isolated caspase-3 with several members having K i values in the 100 to 500 nM range, typically one needs 5-to 10-fold or higher concentrations to inhibit caspase-3 in intact cells (and downstream measures of caspase-3 activity). A 10-fold loss in potency from enzyme to whole cell assay is not unusual when pursuing inhibitors of intracellular targets, e.g., protein kinases. The difference in inhibitor potencies for the isolated enzyme versus a cell response may be due to one of several possibilities including poor cell penetration, metabolism by the cell, protein binding, and/or high enzyme catalytic activity, which requires the need to inhibit Ͼ90% of the active enzyme before seeing efficacy in a cell response. The efficacy of these compounds in the cellular assays is not due to an induction of oncosis and thereby redirecting cell death via a nonapoptotic pathway. The AQZs show no cytotoxic activity at 10 M as measured by the Alamar Blue assay, trypan blue exclusion, or lactate dehydrogenase release (data not shown).
The NGF withdrawal model has been widely used to explore the biochemical pathways involved in the induction and regulation of apoptosis in a neuronal-like environment. The results from these studies indicate that caspase-3 is activated as part of the apoptotic response and plays an important role in the execution phase of apoptosis (Haviv et al., 1997; Kim et al., 1999) , although studies with peptide inhibitors have suggested that a separate caspase-2 pathway is also involved in the death process (Stefanis et al., 1998) . These results required the use of very high concentrations of peptide inhibitors (relative to that required to inhibit the isolated enzyme) to achieve adequate cell exposure. It is possible that under such conditions the selectivity profile of these inhibitors is lost, and/or the compounds act on other biochemical processes. Indeed, the caspase-3 peptidic inhibitor z-DEVD-fmk has proapoptotic activity in PC12 cells under conditions where the isatin sulfonamides are protective . The results in Fig. 7 indicate that caspase-3-selective AQZs can prevent DNA fragmentation in PC12 cells and do so at concentrations where they do not inhibit caspase-2. These results support the role of caspase-3 as a key caspase in the apoptotic pathway activated upon withdrawal of NGF.
The AQZs represent new tools to further explore the role of caspase-3 in various cellular models of apoptosis. This should facilitate a better understanding of in vivo settings where this enzyme plays a critical function in the execution of the apoptotic death response. Such studies will help elucidate both the therapeutic value and potential mechanism-based side effect liabilities of caspase-3 inhibition. 
